Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 74

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 74
---
 ​ | ​ |
| Private Placement of Common Equity (PIPE) | ​ | ​ | ​          | ​ | 15.0 | ​ | ​ |
| Total Sources of Funds                    | ​ | ​ | ​          | $ | 17.3 | ​ | ​ |

10

TABLE OF CONTENTS

| Uses of funds                 | ​ | ​ | $Millions |   |      |   | ​ |
|:------------------------------|:--|:--|:----------|:--|-----:|:--|:--|
| Loan Payoff                   | ​ | ​ | ​         | $ |  1.5 | ​ | ​ |
| Cash on Balance Sheet         | ​ | ​ | ​         | ​ |  4.7 | ​ | ​ |
| Transaction Fees and Expenses | ​ | ​ | ​         | ​ | 11.1 | ​ | ​ |
| Total Uses of Funds           | ​ | ​ | ​         | $ | 17.3 | ​ | ​ |

The Iris Board’s Reasons for Approving the Business Combination On November 30, 2022, the Iris Board: (i) determined that the Business Combination was advisable to and in the best interests of Iris and its stockholders, (ii) unanimously approved the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination), and (iii) recommended that Iris’s stockholders approve the Business Combination Agreement and the transactions contemplated thereby (including the Business Combination). On November 30, 2022, the Business Combination Agreement was executed by the parties. The Registration Statement was initially declared effective by the SEC on August 9, 2024. On August 16, 2024, Liminatus informed us that TDT, Liminatus’s license partner for the intellectual property and other rights related to GCC (CAR-T therapy and cancer vaccine), terminated the TDT License. Following the receipt of the termination notice, and after considering the development status of the CAR-T products, Liminatus management concluded, in its business judgment, that notwithstanding the loss of the TDT License and considering the pre-clinical advancement and market potential of its CD47 asset, to proceed with its business plan without the TDT License. On September 18, 2024, the Iris Board: (i) determined that, notwithstanding the TDT License Termination, the Business Combination was advisable to and in the best interests of Iris and its stockholders, (ii) unanimously approved the Business Combination